| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
294,856 |
134,871 |
$13.66M |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
49,892 |
35,043 |
$5.58M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
136,790 |
72,894 |
$5.05M |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
49,633 |
32,932 |
$3.36M |
| 82075 |
|
169,426 |
83,691 |
$2.73M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
30,811 |
28,569 |
$2.12M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
37,935 |
35,562 |
$1.92M |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
16,116 |
11,252 |
$1.61M |
| 90837 |
Psychotherapy, 53 minutes with patient |
17,102 |
10,721 |
$1.09M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
15,001 |
10,881 |
$759K |
| 81025 |
|
77,074 |
37,337 |
$628K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
18,995 |
17,820 |
$570K |
| 90832 |
Psychotherapy, 30 minutes with patient |
13,343 |
8,898 |
$485K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
34,275 |
18,932 |
$454K |
| T2023 |
Targeted case management; per month |
1,055 |
993 |
$312K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
3,158 |
2,584 |
$311K |
| T1015 |
Clinic visit/encounter, all-inclusive |
2,331 |
1,309 |
$190K |
| 90834 |
Psychotherapy, 45 minutes with patient |
3,856 |
3,017 |
$179K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
5,990 |
5,217 |
$176K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
13,140 |
10,224 |
$172K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
6,305 |
4,216 |
$165K |
| T1007 |
Alcohol and/or substance abuse services, treatment plan development and/or modification |
2,728 |
2,444 |
$136K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
22,747 |
20,002 |
$132K |
| H2036 |
Alcohol and/or other drug treatment program, per diem |
541 |
83 |
$120K |
| G2087 |
Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month |
5,024 |
4,282 |
$108K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
4,788 |
2,093 |
$70K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
968 |
915 |
$65K |
| 99406 |
|
3,378 |
1,782 |
$61K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
670 |
635 |
$53K |
| H0031 |
Mental health assessment, by non-physician |
669 |
607 |
$51K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,219 |
1,083 |
$46K |
| H0001 |
Alcohol and/or drug assessment |
1,057 |
842 |
$41K |
| 80347 |
|
1,828 |
1,189 |
$38K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
1,331 |
1,204 |
$37K |
| 99222 |
Initial hospital care, per day, moderate complexity |
1,024 |
939 |
$34K |
| 99385 |
|
351 |
334 |
$33K |
| 80364 |
|
1,828 |
1,193 |
$32K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
247 |
235 |
$21K |
| 1034F |
|
2,382 |
1,287 |
$21K |
| 90791 |
Psychiatric diagnostic evaluation |
336 |
297 |
$20K |
| 99215 |
Prolong outpt/office vis |
274 |
230 |
$19K |
| 80355 |
|
1,862 |
1,204 |
$18K |
| 80348 |
|
1,826 |
1,197 |
$18K |
| 80373 |
|
1,828 |
1,192 |
$18K |
| 80354 |
|
1,821 |
1,193 |
$18K |
| 80368 |
|
1,820 |
1,190 |
$18K |
| G2088 |
Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; each additional 30 minutes beyond the first 120 minutes (list separately in addition to code for primary procedure) |
2,009 |
1,556 |
$17K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
173 |
157 |
$16K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,119 |
892 |
$16K |
| 80074 |
|
510 |
490 |
$14K |
| H0004 |
Behavioral health counseling and therapy, per 15 minutes |
282 |
161 |
$14K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
165 |
156 |
$13K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
242 |
207 |
$12K |
| 99386 |
|
103 |
97 |
$12K |
| 80361 |
|
460 |
363 |
$8K |
| 80349 |
|
790 |
514 |
$7K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
512 |
490 |
$7K |
| 80369 |
|
683 |
482 |
$7K |
| 99407 |
|
229 |
208 |
$7K |
| 80359 |
|
679 |
477 |
$7K |
| 80339 |
|
680 |
478 |
$7K |
| 86696 |
|
515 |
493 |
$6K |
| 36415 |
Collection of venous blood by venipuncture |
1,245 |
1,168 |
$6K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
379 |
240 |
$5K |
| 80356 |
|
475 |
376 |
$5K |
| 80324 |
|
492 |
336 |
$5K |
| 80366 |
|
457 |
361 |
$5K |
| 80365 |
|
457 |
363 |
$5K |
| 80061 |
Lipid panel |
474 |
452 |
$5K |
| 80336 |
|
453 |
360 |
$5K |
| 84443 |
Thyroid stimulating hormone (TSH) |
550 |
524 |
$4K |
| 86695 |
|
516 |
494 |
$4K |
| 83992 |
|
290 |
242 |
$4K |
| 82728 |
|
448 |
420 |
$4K |
| 82607 |
|
423 |
404 |
$4K |
| 80345 |
|
315 |
267 |
$3K |
| 82746 |
|
415 |
399 |
$3K |
| 80353 |
|
294 |
247 |
$3K |
| 80367 |
|
287 |
241 |
$3K |
| 99223 |
Prolong inpt eval add15 m |
60 |
50 |
$3K |
| 80334 |
|
284 |
238 |
$3K |
| 80358 |
|
275 |
228 |
$3K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
599 |
552 |
$3K |
| 80050 |
General health panel |
59 |
58 |
$3K |
| 80053 |
Comprehensive metabolic panel |
578 |
537 |
$3K |
| 99409 |
|
123 |
108 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
190 |
178 |
$2K |
| 99348 |
|
135 |
116 |
$2K |
| 99401 |
|
109 |
94 |
$2K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
101 |
101 |
$2K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
61 |
55 |
$2K |
| 80325 |
|
182 |
123 |
$2K |
| H0049 |
Alcohol and/or drug screening |
132 |
114 |
$1K |
| 86592 |
|
509 |
485 |
$1K |
| 99349 |
|
53 |
42 |
$1K |
| 99490 |
Ccm add 20min |
43 |
42 |
$1K |
| 99221 |
|
54 |
53 |
$1K |
| 80305 |
|
148 |
129 |
$1K |
| 86580 |
|
58 |
51 |
$962.76 |
| 87807 |
|
90 |
88 |
$843.35 |
| 96127 |
|
131 |
109 |
$819.52 |
| 87428 |
|
17 |
15 |
$734.89 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
119 |
109 |
$689.32 |
| 80076 |
|
367 |
345 |
$619.99 |
| 99051 |
|
182 |
128 |
$539.35 |
| 99219 |
|
19 |
15 |
$507.69 |
| 99441 |
|
13 |
12 |
$413.90 |
| 82550 |
|
85 |
77 |
$409.18 |
| 99439 |
|
13 |
13 |
$389.09 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
42 |
34 |
$334.40 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
421 |
383 |
$291.35 |
| 86141 |
|
36 |
35 |
$288.49 |
| 99217 |
|
15 |
14 |
$244.53 |
| 85652 |
|
77 |
72 |
$161.70 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
15 |
14 |
$78.40 |
| 81002 |
|
30 |
28 |
$71.84 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
31 |
28 |
$56.61 |
| 81003 |
|
14 |
12 |
$0.00 |
| 99000 |
|
491 |
417 |
$0.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
28 |
26 |
$0.00 |